Medicinal Usage of Cannabis and Cannabinoids

There is a growing body of data supporting the usage of cannabis and cannabis-related products in alleviating or preventing symptoms in different diseases and conditions. Medicinal Usage of Cannabis and Cannabinoids offers readers a comprehensive reference on the medical usage and symptom relief provided by these compounds in a variety of disorders. With coverage of neurological diseases like Alzheimer's and Parkinson's, and a wide range of other afflictions including depression, anxiety, nausea, and cancer, this broad coverage allows readers to learn about symptom control but also physiological, psychological, and pharmacological effects of these compounds. Unique case reports are provided as well. This volume provides a platform for research on the use of these compounds in improving patient care, brain function, and neurological dysfunction. Summarizes the medicinal usage of cannabis and cannabinoids in a variety of conditions Contains chapter abstracts, key facts, dictionary, and summary Examines symptom control of conditions including depression, anxiety, and sleep Discusses cannabis usage in Alzheimer's, Parkinson's, Multiple Sclerosis, and cancer Features case reports and chapters on physiological, psychological, and pharmacological effects INDICE: Section 1: Introductory Chapters and Setting the Scene 1. What medicinal cannabis is used for: a focus on Canada Prof. D.T. Eurich, School of Public Health, University of Alberta, 2-040 Li Ka Shing HRIF, Edmonton T6G2E1, Canada. 2. Cannabidiol (CBD) Oil: Google trends Prof. S. Narayanan, Department of Palliative, Rehabilitation and Integrative Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Unit 1414, 1515 Holcombe Boulevard, Houston, TX 77030, United States. 3. Free medicinal cannabis: Behavior of veterans Prof. M.J.E. Loflin, Center of Excellence for Stress and Mental Health, San Diego Healthcare System, United States. 4. Medicinal use of cannabis: adverse events as a balanced perspective Prof. N. Lombardi, Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy. Or Prof. M.R. Pearson, Center on Alcoholism, Substance Abuse and Addictions, University of New Mexico, 2650 Yale Blvd South East, M-Albuquerque, NM 87106, Mexico. Section 2a: Cannabinoids for Symptom Relief 5. The endocannabinoid-glutamate system and pain Prof. N. Stensson, Pain and Rehabilitation Centre, Department of Medical and Health Sciences, Linkoping University, Linkoping, Sweden. 6. The endocannabinoid system and antidepressant activity of bupropion Prof. E. Poleszak, Laboratory of Preclinical Testing, Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, Chodzki 1, Lublin 20-093, Poland 7. Linking cannabis with depression, anxiety and flourishing Prof. A. Butler, School of Public Health and Health Systems, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada OR Anxiety, and depression: cannabis and cannabinoids as a treatment Prof. J.D. Kosiba, Department of Psychology, Syracuse University, Syracuse, NY 13244, United States. 8. Hippocampal CB1, CB2 receptors and fear memory Prof. C.A.J. Stern, Department of Pharmacology, Federal University of Parana, Curitiba, Brazil. 9. Cannabinoid receptor 2 agonists and neuropathic pain Prof. J.R. Lokensgard, Neurovirology Laboratory, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, United States. 10. 2-Arachidonoyl glycerol as a cannabimimetics: applications to anxiety and stress Prof. S. Patel, Vanderbilt University Medical Center, Medical Research Building IV, Room 8425B, 2213 Garland Avenue, Nashville, TN 37232, United States. 11. 2- arachidonoyl glycerol and headache Prof. M. Allena, Headache Science Centre, IRCCS Mondino Foundation, Pavia, Italy. 12. Anandamide, fatty acid amide hydrolase and attentional impairments Prof. F. Papaleo, Department of Neuroscience and Brain Technologies, Genetics of Cognition Laboratory, Istituto Italiano di Tecnologia, Genova, Italy. 13. Anandamide, stress and fear Prof. M. Heilig, Center for Social and Affective Neuroscience, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden. 14. Anandamide and neuroinflammation Prof. F.J.M. Maron, Departamento De Patologia, Facultad De Ciencias Medicas, Universidad Nacional De Cuyo (IMBECUCONICET), Mendoza, Argentina. Section 2b: Endocannabinoids for Disorders 15. Alzheimer's disease: cannabis and cannabinoids as a treatment Prof. T.H. Yook, Department of Acupuncture & Moxibustion Medicine, Korean Medicine Hospital of Woosuk University, 46, Eoeun-ro, Wansan-gu, Jeonju 54987, South Korea. OR The endocannabinoid system in Alzheimer's disease Prof. V. Di Marzo, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy OR Prof. J.A. Paez, Instituto de Quimica Medica (IQM-CSIC), C/ Juan de la Cierva, 3, Madrid 28006, Spain. 16. Asthma: cannabis and cannabinoids use as a treatment Prof. Jo.G. Bramness, Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Innlandet Hospital Trust, P.O. Box 104, Hamar, Norway. 17. Autism: cannabis and cannabinoids use as a treatment Prof. M. Berkovitch, Clinical Pharmacology and Toxicology Unit, Assaf Harofeh Medical Center, Tel Aviv, Israel. 18. Autoimmune Hepatitis: cannabis and cannabinoids use as a treatment Prof. C. Lammert, Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, 702 Rotary Circle, Suite 225, Indianapolis, IN 46202, United States. 19. Posttraumatic Stress Disorder: therapeutic cannabis and cannabinoids use as a treatment Prof. Y. Zhang, Department of Psychiatry, College of Medicine, University of Saskatchewan, 119 Ellis Hall, 103 Hospital Drive, Saskatoon, SK S7N 0W8, Canada. 20. Cancer Patients: Attitudes and beliefs of cannabis and cannabinoids use as a treatment Prof. K. Tanco, Department of Palliative, Rehabilitation, and Integrative Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1414, Houston, TX 77030, United States. 21. Chronic kidney disease: cannabis and cannabinoids use as a treatment control Prof. C. Ho, Fraser Health Renal Program, Surrey, BC, Canada. 22. Epilepsy: cannabis and cannabinoids use as a treatment Prof. A. Carter, Department of Neurology, University of Saskatchewan, College of Medicine, Stonebridge Neurology Clinic, 250-510 Cope Way, Saskatoon, SK S7T0G3, Canada. 23. Gastrointestinal Symptoms: cannabis and cannabinoids use as a treatment control Prof. B. Zemrani, Pediatric Gastroenterology-Hepatology-Nutrition Unit, Necker-Enfants-Malades Hospital, Paris, France. OR Prof. T.A. Zikos, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 430 Broadway St., Pavilion C, 3rd Floor, GI Suite, Redwood City, CA 94063, United States. 24. Gastroparesis: cannabis and cannabinoids use as a treatment Prof. H.P. Parkman, NIH Gastroparesis Clinical Research Consortium, Bethesda, MD, United States. 25. Gynecologic malignancies: cannabis and cannabinoids use as a treatment Prof. E.A. Blake, Department of Gynecologic Oncology, University of Southern California, 2020 Zonal Ave., Room 522, Los Angeles, CA 90033, United States. 26. Glaucoma: cannabis and cannabinoids use as a treatment Prof. A.P. Costarides, Emory University, Atlanta, GA, United States. or Prof. S. Majumdar, Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, 111 Faser Hall, Oxford, MS 38677, United States. 27. HIV: cannabis and cannabinoids use as a treatment Prof. C.T. Costiniuk, Chronic Viral Illness Service, Division of Infectious Diseases, McGill University Health Centre, Montreal, QC, Canada. 28. Mental disorders: treatments with cannabis and cannabinoids as a treatment Prof. L. Degenhardt, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia. 29. Migraine and Anandamide Prof. A.B. Oliveira, Universidade Federal de Sao Paulo, Sao Paulo 04039-032, Brazil. 30. Multiple sclerosis: treatments with cannabis and cannabinoids as a treatment Prof. A. Hildebrand, Oregon Health and Science University, VA Portland Health Care System, P3MSCOE, 3710 SW US Veterans Hospital Road, Portland, OR 97239, United States. 31. Myotonia: use of cannabis and cannabinoids as a treatment Prof. F. Montagnese, Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University Munich, Ziemssenstr. 1, Munich 80336, Germany. 32. Noncancer pain: A narrative of medicinal cannabis and cannabinoids use as a treatment Prof. I. Gilron, Department of Anesthesiology and Perioperative Medicine, Queen's University, 76 Stuart Street, Kingston, ON K7L 2V7, Canada. 33. Obesity and 2-Arachidonoylglycerol: involvement of the neurological systems Prof. E.C. Hanlon, Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago, 5841 S. Maryland Ave, MC 1027, Chicago, IL 60637, United States. 34. Palliative care and hospices: medicinal cannabis and cannabinoids practices Prof. M.L. McPherson, Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD 21201, United States. OR Prof. D.J. Casarett, Department of Medicine, Duke University, Durham, NC 27707, United States. 35. Parkinson's disease A narrative of medicinal cannabis and cannabinoids use Prof. J.A.S. Crippa, Hospital das Clinicas, Terceiro Andar, Av. Bandeirantes, 3900, Ribeirao Preto, Sao Paulo CEP-14049-900, Brazil. OR The endocannabinoid system in Parkinson's disease Prof. J. Ceccarini, Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium. 36. Sleep: cannabis and cannabinoids use Prof. E. Murillo-Rodriguez, Laboratorio de Neurociencias Moleculares e Integrativas, Escuela de Medicina, Division Ciencias de la Salud, Universidad Anahuac Mayab, Carretera pop Merida-Progreso Km. 15.5, A.P. 96 Cordemex, Merida, Yucatan C.P. 97310, Mexico. 37. The endocannabinoid system and impact in traumatic brain injury Prof. P.E. Molina, Department of Physiology, Louisiana State University Health Sciences Center, 1901 Perdido Street, New Orleans, LA 70112, United States. 38. Inhibitions of anandamide transport, TRPV1 channels and seizures Prof. M. Naziroglu, Department of Biophysics, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey. 39. Fatty acid amide hydrolase, the endocannabinoid anandamide and neurological disease Prof. M. Maccarrone, European Center for Brain Research/IRCCS Santa Lucia Foundation, Via del Fosso di Fiorano 64, Rome 00143, Italy. 40. Quality of life in the nursing context: cannabis and cannabinoids use for symptom Prof. Z.J. Palace, Medicine, Hebrew Home at Riverdale, 5901 Palisade Ave, Bronx, NY 10471, United States. 41. Urinary tract symptoms: medicinal cannabis and cannabinoids uses Prof. R.B. Nadler, Department of Urology, Northwestern University Feinberg School of Medicine, 675 N. Saint Clair St., Suite 20-1502, Chicago, IL 60611, United States. Section 3: Case Reports

• ISBN: 978-0-323-90036-2
• Editorial: Academic Press
• Encuadernacion: Cartoné
• Páginas: 730
• Fecha Publicación: 01/06/2023
• Nº Volúmenes: 1
• Idioma: Inglés